If this email is not displaying properly or to share with a colleague, please View as Webpage

After a successful pilot, the PCSS-Exchange (PCSS-X) is beginning a new round of live Zoom webinars on the implementation of prescribing medications for opioid use disorder beginning Nov. 19.

PCSS-X is a six-session course focused on implementing prescribing medications for treating opioid use disorder in a variety of healthcare settings. The course content will be built around the EPIS (Explore, Prepare, Implement, Sustain) Framework of implementation.

PCSS-X is intended for an interprofessional audience, and participants are welcome to attend whichever sessions are most relevant to their current situation. Prescribers with frontline experience prescribing MAT and developing clinic workflows will be available during each session to answer participants’ questions and discuss real-world cases.

Registration and more information about each session coming soon!

Date: Tuesday, November 10, 2020

Time: 12:00 pm - 1:00 pm

Presenter: Yavar Moghimi, MD

Sponsoring organization: American Psychiatric Association

About this webinar: This webinar will provide an overview of the evidence of medication-assisted treatments (MAT), such as buprenorphine or methadone, as an effective preventative method against blood-borne viruses commonly associated with injection opioid use such as hepatitis C virus (HCV) [Learn more]

All PCSS webinars are recorded and are available for on demand viewing, usually within two weeks of live webinar (and often sooner). Recent webinars that are now available:

(American Academy of Addiction Psychiatry)

(American Psychiatric Association, American Academy of Addiction Psychiatry)

(American Dental Association)

(American Psychiatric Association, American Academy of Addiction Psychiatry)

See list of all recorded webinars.

Upcoming PCSS Clinical Roundtables:

Nov. 10, 12:00 pm - 1:00 pm*

Nov. 17, 12:00 pm - 1:00 pm (It is recommended participants view the webinar prior to

attending this roundtable)

Credit Designations Available: AMA PRA Category 1 Credit™, and Interprofessional Continuing Education (IPCE) credit.

* All times are ET

The “Implementation of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment” is now available to view in the Federal Register. There will be a 60-day comment period and the comments will be addressed in the Final Rule. This rule will be implementing some of the changes to the Controlled Substances Act made by the “Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018 (the SUPPORT Act),” which became law on October 24, 2018. 

In particular, DEA will be expanding the conditions a practitioner must meet to provide medication-assisted treatment and expanding the options available for a physician to be considered a qualifying physician. As done by the SUPPORT Act, this rule will be also removing the time period for a nurse practitioner or physician assistant to be considered a qualifying other practitioner, and revising the definition of a qualifying practitioner. This rule will also allow a pharmacy to deliver prescribed controlled substances to a practitioner’s registered location for the purpose of maintenance or detoxification treatment to be administered under certain conditions by a practitioner, which is consistent with the SUPPORT Act. This interim final rule is expected to increase the number of DATA-waived providers.

Comments close January 4, 2021, and is expected to garner a large amount of attention from the registrant community. [Learn more]

The ATTC Network has created a core curriculum training package to provide information about central nervous system stimulants and their impact on brain, body, and behavior. Prepared by members of the Addiction Technology Transfer Center Network, Stimulant Workgroup, the training covers (1) the scope of stimulant use in the United States and beyond; (2) stimulants and the brain and impact of use on cognition; (3) stimulant use and psychosis; (4) short- and long-term physical and mental health consequences of stimulant use and considerations for specific populations; (5) the intersection of stimulant use and HIV risk; and (6) effective evidence-based behavioral treatment interventions and recovery supports for people with a stimulant use disorder. [Learn more]

Funding for this initiative was made possible (in part) by grant no. 1H79TI081968 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.